RapidAI (formerly iSchemaView Inc.)

Golden, CO, United States  All United States companies → — Founded 2011
Imaging AI Specialist
Emergency Medicine Neurosurgery Radiology
Neurology AI Radiology & Imaging AI Triage & ER/ICU AI
Series C
Claim this company

Products

Rapid Obstructive Hydrocephalus
RapidAI
Neurology AI
Rapid OH is an FDA-cleared AI tool by RapidAI for the rapid detection and triage of suspected obstructive hydrocephalus from non-enhanced CT head images, providing automated alerts for workflow prioritization.

See all 1 product →

About RapidAI (formerly iSchemaView Inc.)

RapidAI, formerly iSchemaView Inc., is a leading healthcare AI company specializing in advanced imaging for life-threatening vascular and neurovascular conditions. Their core offering is the Rapid® platform, an AI-enabled software that processes CT and MRI scans to provide rapid, accurate diagnostic and treatment insights for conditions such as stroke, cerebral aneurysms, and pulmonary embolism. The platform goes beyond simple detection, offering deep clinical AI for triage, localization, quantification, characterization, visualization, and longitudinal tracking of anomalies.

For physicians, the RapidAI platform aims to enhance diagnostic confidence and streamline workflows by connecting radiology, specialists, and care teams. It provides real-time insights and supports clinical decision-making, which has been instrumental in expanding stroke treatment windows based on landmark clinical trials. The platform is deployed in over 2,200 hospitals across more than 100 countries and is supported by extensive clinical evidence, including over 700 publications. RapidAI also offers solutions for life sciences, assisting in clinical trial design, patient enrollment, and data analysis.

Focus Areas

Neurovascular Cardiac & Vascular Radiology Life Sciences Stroke Aneurysm Pulmonary Embolism Trauma Clinical Decision Support AI-driven Imaging Workflow Solutions

Business Intelligence

TechnologyRapid Enterprise™ Platform, Deep Clinical AI, Rapid Edge Cloud (cloud-native with on-prem capabilities), AI operating system, Mobile App, Navigator Pro, Rapid Insights, Third-party integration (PACS, EMR)

What Physicians Need to Know

Neurovascular & Stroke
RapidAI is a global leader in AI-driven neurovascular care, offering solutions for stroke detection, assessment, and treatment. Their platform aids in identifying large vessel occlusions (LVOs) and intracranial hemorrhages (ICH) with high sensitivity and specificity, reducing time to diagnosis and treatment. RapidAI's software can quickly detect anterior circulation LVOs (mean time 3 minutes 30 seconds) and has been shown to improve diagnostic confidence and accuracy for distal vessel occlusions (DVOs). The company's technology also assists in expanding the treatment window for ischemic stroke from approximately six to 24 hours. RapidAI has demonstrated superior accuracy in detecting medium vessel occlusions (MeVOs) compared to other AI solutions.
Aneurysm
RapidAI's Rapid Aneurysm platform enhances diagnostic accuracy and consistency in detecting intracranial aneurysms, particularly those that are nuanced or hard to visualize. A large real-world study showed it helped identify nearly 23% more aneurysms than original radiology reports, especially those ≥ 3mm in size, with a sensitivity of 92.5% and specificity of 96.4%. The platform combines 3D visualization, growth tracking, and automated measurement, providing clinicians with a comprehensive view and confidence in their decisions. It has also been shown to detect 46% more clinically significant aneurysm growth over time compared to neuroradiologists' interpretations alone.
Pulmonary Embolism (PE)
RapidAI offers AI-powered solutions for the rapid diagnosis and management of pulmonary embolism. Their Rapid PE Triage & Notification tool automatically analyzes CT pulmonary angiograms (CTPA) for signs of PE and immediately alerts the care team via mobile and desktop apps. This aims to speed up diagnosis and treatment initiation. RapidAI also has FDA clearance for Rapid RV/LV, a program that calculates heart metrics associated with PE severity, helping identify patients with possible right heart strain and reducing variability in measurements.
Radiology & AI-driven Imaging
RapidAI provides enterprise radiology solutions with deep clinical AI for interpretation, workflows, and care team collaboration. Their platform offers advanced 3D visualization without manual reconstruction, including automated curved planar reformats and high-quality 3D MIPs and volume renderings. RapidAI integrates with PACS to prioritize urgent cases and those with acute findings, improving turnaround times. The company's AI goes beyond simple triage and notification to provide specific, relevant, and contextual data with high accuracy.
Clinical Decision Support & Workflow Solutions
RapidAI's platform delivers deep clinical decision support for various disease states, empowering care teams to rapidly, precisely, and confidently manage life-threatening conditions. It facilitates real-time collaboration and alerts for urgent cases through its mobile app. The solutions are designed to reduce cognitive burden, enhance decision-making, and seamlessly fit into existing workflows. RapidAI's workflow solutions help align, activate, and communicate about patient status to administer care faster, as seen with their Rapid Workflow for PE.
Technology Stack & Infrastructure
RapidAI utilizes an edge-to-cloud platform, which is described as the only one of its kind in the healthcare industry. This hybrid infrastructure combines cloud scalability with on-premise resilience, ensuring fast processing, continuous uptime, and enterprise-grade security. This allows for processing AI models on both edge and cloud, running multiple algorithms in parallel, and dynamically switching between cloud and on-premise in case of cyber events. The Rapid Enterprise™ Platform is designed for cross-disciplinary deployment of deep clinical AI and integrates directly within PACS, EHR, worklists, and care-team tools.
Physician Tip

For physicians, RapidAI's solutions offer decision-grade analysis, quantification, and clinical context to move from imaging to action faster. Radiologists can expect to read faster and easier with AI for interpretation, workflows, and care team collaboration, while care teams can act faster with shared imaging insights and real-time communication. The platform aims to reduce administrative burdens, enhance decision-making, and provide consistent, high-quality reads across long shifts. RapidAI's deep clinical AI goes beyond simple detection to provide deeper insights, supporting more informed decisions and reducing the strain of starting every case from scratch.

RapidAI's Rapid Enterprise™ Platform is built for seamless integration across PACS, EHR, worklists, reporting systems, and even third-party algorithms. It supports a careful selection of vetted third-party algorithms and can accommodate hospitals with unique requests or their own developed algorithms on a single platform. This vendor-agnostic integration and scalable infrastructure are designed for minimal lift in existing hospital stacks.

Products by RapidAI (formerly iSchemaView Inc.)

1 product in the directory

Rapid Obstructive Hydrocephalus
RapidAI
Neurology AI
Rapid OH is an FDA-cleared AI tool by RapidAI for the rapid detection and triage of suspected obstructive hydrocephalus from non-enhanced CT head images, providing automated alerts for workflow prioritization.

What the Web Says

RapidAI, formerly iSchemaView Inc., develops AI-driven imaging solutions primarily for stroke, trauma, and vascular conditions, analyzing brain scans to assist physicians in diagnosis and treatment. The company's platform aims to expedite treatment decisions by providing results within minutes and integrates into hospital systems via PACS and mobile apps. While the product receives positive feedback for its speed and accuracy in detecting conditions like intracranial hemorrhage and large vessel occlusion, employer reviews highlight significant concerns regarding management, culture, and job security.

Overall: Mixed

Strengths

  • RapidAI's software is highly accurate in detecting intracranial hemorrhage (ICH) and large vessel occlusion (LVO) in stroke patients.
  • The platform provides results quickly, often within 1-2 minutes for ICH and LVO detection, which is crucial for timely stroke treatment.
  • The technology helps focus radiologists' interpretation to specific regions of anatomy and facilitates faster patient transfers.
  • RapidAI integrates into existing hospital systems, including PACS and mobile apps, and supports interoperability with third-party healthcare systems and EMRs.
  • The company offers a flexible vacation policy and covers 100% of employee medical, dental, and vision premiums.
  • The technology is backed by extensive clinical validation, with over 750 peer-reviewed papers and 25+ clinical trials.

Limitations

  • Several employer reviews describe a toxic sales culture and micromanagement.
  • There are serious concerns about the executive team, with reports of high turnover and mental abuse leading to medical leave for some employees.
  • Job security and advancement opportunities are rated poorly by employees.
  • The cost-effectiveness of RapidAI for stroke detection is currently unknown, and there is limited evidence on its impact on patient harms, mortality, or quality of life.
  • Some AI diagnostic tools, including those for pulmonary embolism and intracranial hemorrhage, have been reported to have false positives or miss obvious findings by radiologists on Reddit.
  • G2 and Capterra have limited direct product reviews for RapidAI, making it difficult to gauge widespread user satisfaction from these platforms.

Based on reviews from: Indeed.com, Elion Health, Reddit, NCBI Bookshelf, Slashdot, Healthcare IT Reviews, Working Nomads, Healthcare IT Today, MedIndexer, RadAISlice, G2, Capterra

Last updated: 2026-10-26

Videos

News, demos, and interviews about RapidAI (formerly iSchemaView Inc.).

Loading videos...

Videos load interactively. If none appear, search YouTube for RapidAI (formerly iSchemaView Inc.) →

View all on YouTube

Press & Coverage

Drug and Device World
RapidAI wins FDA nod for five new AI tools
RapidAI received FDA clearance for five new AI modules: Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic, expanding its clinical AI platform for neurology, vascular, and radiology care. These tools are designed to enhance disease characterization, quantification, and tracking over time.
2025-11
RapidAI (via Business Wire)
RapidAI Announces $75 Million Growth Investment Led by Vista Credit Partners
RapidAI secured $75 million in Series C funding led by Vista Credit Partners to accelerate platform innovation for various disease states and expand its market reach. The company has surpassed 10 million scans analyzed and has over 300 peer-reviewed publications.
2023-07
RapidAI (via Business Wire)
RapidAI Highlights Research Depth and Industry Leadership at ISC 2026 With 28 Clinical Abstracts
RapidAI presented 28 scientific abstracts at the International Stroke Conference (ISC) 2026, covering aneurysm monitoring, ischemic stroke detection, and radiology workflow optimization. These findings demonstrate the impact of their deep clinical AI platform in improving diagnostic performance and efficiency.
2026-02
RapidAI (via Business Wire)
OSF HealthCare expands use of RapidAI among all hospitals
OSF HealthCare expanded its partnership with RapidAI, deploying the Rapid Enterprise™ Platform to all 18 of its hospitals. This expansion aims to provide advanced AI solutions for medical image analysis, care team connectivity, and patient management across the health system.
2026-08
Business Wire
RapidAI Extends the Reach of Deep Clinical AI with Five New FDA Clearances
RapidAI announced five new FDA clearances for imaging modules, including Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic. These clearances significantly expand the Rapid Enterprise Platform, reinforcing RapidAI's focus on deep clinical AI for comprehensive patient management.
2025-11
Imaging Technology News
AWS, RapidAI Team Up to Accelerate Global Deployment of Deep Clinical AI
RapidAI and Amazon Web Services (AWS) strengthened their collaboration to accelerate the global adoption and scalability of deep clinical AI in healthcare. This partnership focuses on co-development and go-to-market alignment, leveraging AWS's infrastructure with RapidAI's clinical expertise.
2025-12
RapidAI (via Business Wire)
RapidAI Announces Late-Breaking Abstract Simultaneously Published in NEJM
RapidAI announced the publication of the TIMELESS trial in the New England Journal of Medicine (NEJM), reinforcing the RapidAI platform's role in advancing stroke care. The study's findings, along with other research presented at ISC 2024, highlight the company's growing clinical evidence.
2024-02
Business Wire
The Innovator in AI Enhanced Stroke Imaging Officially Becomes RapidAI
iSchemaView, a pioneer in AI-enhanced stroke imaging, officially rebranded as RapidAI, reflecting its leadership in artificial intelligence for advanced imaging. The company also unveiled new branding, a website, and a technology partner program at ISC 2020.
2020-02

Frequently Asked Questions

RapidAI's platform provides AI-powered solutions for the detection and analysis of various acute neurovascular conditions like stroke (ischemic and hemorrhagic), aneurysms, and other cerebrovascular diseases. It also extends to cardiac and vascular emergencies, including pulmonary embolism, by offering rapid image processing and clinical decision support for these critical conditions.
RapidAI prioritizes compliance with global healthcare regulations and data privacy standards such as HIPAA and GDPR. The company implements robust security measures and data anonymization protocols to protect patient information while ensuring the integrity and privacy of imaging data processed through its AI platform.
RapidAI's pricing model is generally tailored to the specific needs and scale of the healthcare institution, often involving subscription-based licenses for its AI-driven imaging and workflow solutions. Pricing can vary based on the modules implemented (e.g., Neurovascular, Cardiac), the volume of studies, and the size of the hospital or health system, with customized options available for academic institutions.
RapidAI provides comprehensive technical support and clinical training to facilitate seamless integration and optimal utilization of its AI platform. This includes on-site and remote training for physicians, radiologists, and IT staff, along with ongoing technical assistance and dedicated customer success teams to address any operational or clinical queries.
Yes, RapidAI's solutions are designed for seamless integration with existing hospital IT infrastructure, including Picture Archiving and Communication Systems (PACS), Electronic Medical Records (EMR), and other critical systems. This ensures a streamlined workflow, allowing for rapid access to AI-powered insights directly within the physician's established clinical environment.
RapidAI is continuously investing in research and development to expand its AI applications beyond its current focus, exploring new vascular territories and broader life sciences research. The company aims to leverage its AI platform to address unmet needs in diagnostics and treatment across a wider range of medical conditions, often through strategic partnerships and collaborations.
RapidAI demonstrates clinical efficacy through extensive validation studies and real-world data showcasing improved patient outcomes, such as faster treatment times and better functional recovery in stroke patients. ROI is typically shown through metrics like reduced length of hospital stay, optimized resource utilization, and enhanced diagnostic accuracy, which contribute to overall cost savings and improved operational efficiency for healthcare systems.

Comparisons

Rapid Obstructive Hydrocephalus vs HealthPNX
Rapid Obstructive Hydrocephalus vs Viz Subdural+
Rapid Obstructive Hydrocephalus vs Viz ANEURYSM
Rapid Obstructive Hydrocephalus vs Viz CTP

Related Companies

A2
A2z Radiology Ai
Boston, MA, USA

A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]
Pe
Perimeter Medical Imaging AI
Toronto, Canada and Dallas, Texas, USA

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
SOPHiA GENETICS
Rolle, Switzerland and Boston, Massachusetts, United States

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]
Koios Care
Antwerp, Belgium

Koios Care is a neurology-focused digital medicine company based in Antwerp, Belgium, specializing in AI-powered platforms. The company aims to revolutionize the management of neurological and chronic conditions, with an initial focus on Parkinson’s Disease. Koios Care’s platform utilizes everyday devices like smartphones and smartwatches to passively collect and analyze data, transforming it into objective, […]
Qure.ai
Mumbai, India

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]
DeepBio
Seoul, South Korea

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]
Suggest an Edit → | Report an issue
AI Tool Finder
AI-powered search. Results may not be comprehensive.